IngredientsGarcinone E is a naturally occurring polyphenolic compound belonging to the xanthone class of secondary metabolites. It carries the CAS Registry Number 112649-21-5 and the molecular formula C28H32O6. Its full IUPAC name, as established by spectroscopic characterization reported in the chemical literature (Sakai et al., Chem. Pharm. Bull., 1993), describes a prenylated trihydroxyxanthone skeleton. Xanthones (9H-xanthen-9-ones) are an important class of heterocyclic compounds containing oxygen and a gamma-pyrone moiety with a two-benzene-ring structure. Within that broader class, garcinone E is specifically classified as a prenylated, oxygenated xanthone — meaning its tricyclic scaffold carries one or more isoprene-derived (prenyl) side chains and multiple hydroxyl substituents that jointly govern its polarity, lipophilicity, and biological reactivity.
Garcinone E shares the same core xanthone scaffold as structurally similar mangosteen prenylated xanthones (α-mangostin, γ-mangostin, and 9-hydroxycalabaxanthone) but exhibits certain structural variations; the different number of isoprenyl moieties and the degree of cyclization affect electron-density delocalization and lipophilicity, which in turn affects pharmacokinetic properties. The presence of an isoprenyl group at position 5 in the structure of garcinone E, compared to γ-mangostin, increases its ability to elevate oxidative stress and to induce a mitochondrial proton leak.
The presence of functional groups such as prenyl, hydroxyl, glycosyl, furan, and pyran at key positions of xanthones may contribute to their broad spectrum of biological activity.
Garcinia mangostana L. (Clusiaceae), a popular tropical fruit prized for its juiciness and sweetness, is an abundant source of prenylated and oxygenated xanthones with a wide array of biological activities. It is cultivated in the tropical rainforests of Southeast Asian nations including Indonesia, Malaysia, Sri Lanka, the Philippines, and Thailand.
Xanthones have been isolated from the pericarp, whole fruit, heartwood, and leaves of G. mangostana. The most studied xanthones from this source are α-, β-, and γ-mangostins, garcinone E, 8-deoxygartanin, and gartanin. To date, approximately 80 bioactive xanthones have been identified and isolated from mangosteen; α-mangostin, γ-mangostin, garcinone C, and garcinone E are the most typical of these bioactive xanthones.
Garcinone E has also been identified in other species within the genus Garcinia. It has been isolated, together with mangostanaxanthones I and II, β-mangostin, 8-hydroxycudraxanthone G, garcinone C, cudraxanthone G, and (−)-epicatechin, from the ethyl acetate-soluble fraction of the air-dried pericarps of Garcinia mangostana (family Clusiaceae).
Garcinone E has been extracted and purified from the rinds (peel) of the fruits of Garcinia mangostana L. using partitioned chromatography. Standard phytochemical workflows used in research involve initial extraction with organic solvents (commonly 95% ethanol, methanol, or ethyl acetate), followed by sequential liquid-liquid partitioning and column chromatographic separation. After evaporation of the collected percolate, the crude extract is typically suspended in water and partitioned with petroleum ether, chloroform, ethyl acetate, and n-butanol successively before further purification by preparative HPLC. Methanol extracts of G. mangostana L. pericarps subjected to column chromatography have yielded garcinone E alongside other known xanthones including α-mangostin, garcinone C, 11-hydroxy-1-isomangostin, and mangostenone E.
As of the date of this article, garcinone E is not available as a standardized commercial dietary supplement formulated for consumer use; it is supplied by chemical vendors exclusively as a research-grade reference compound for laboratory investigation. No finished-product dose forms (capsules, tablets, or standardized extracts) standardized specifically to garcinone E content are documented in the peer-reviewed literature.
Garcinone E itself is an isolated phytochemical that was not identified as a discrete entity until the latter decades of the twentieth century (structure formally described by Sakai et al. in Chemical and Pharmaceutical Bulletin, 1993). Consequently, there is no historical tradition of use for garcinone E as a named, isolated compound. Its traditional context is therefore that of its source plant, the mangosteen fruit pericarp, which has been used medicinally for centuries in its whole or crude-extract form.
Early reports of the traditional uses of infusions and decoctions of mangosteen peels and seeds to treat gastrointestinal and urinary tract infections, and as anti-scorbutic, laxative, and anti-fever agents, date from almost two hundred years ago (Descourtilz et al., 1821; Lilly and Colman, 1833; Pardo de Tavera and Thomas, 1901).
People in Indonesia, Malaysia, Sri Lanka, the Philippines, and Thailand have used the pericarp (peel, rind, hull, or ripe fruit) of G. mangostana as a traditional medicine for the treatment of abdominal pain, diarrhea, dysentery, infected wounds, suppuration, and chronic ulcer.
The pericarp of the mangosteen fruit has been used as a medicinal agent by Southeast Asians for centuries in the treatment of skin infections and wounds, as well as amoebic dysentery. In Ayurvedic medicine the pericarp of the mangosteen fruit has wide use against inflammation and diarrhea, and also against cholera and dysentery.
In traditional medicinal systems, decoctions and infusions prepared from mangosteen fruits have been used effectively to treat skin lesions and various inflammatory conditions. Traditional healers have valued the rind's astringent properties, often boiling it to create poultices or oral remedies for inflammatory conditions and gastrointestinal issues, with records of such practices dating back to at least the 18th century. In Thai traditional medicine, for instance, the dried pericarp is decocted specifically to alleviate dysentery and inflammation.
The seeds and pericarps of the fruit have a long history of use in the traditional medicinal practices of the region, and beverages containing mangosteen pulp and pericarps are sold worldwide as nutritional supplements.
It is important to note that traditional preparations used the whole pericarp or crude extract, which contained a complex mixture of xanthones (including α-mangostin, γ-mangostin, garcinone C, garcinone D, garcinone E, gartanin, and many others) as well as other phytochemicals. The specific bioactivity attributed to garcinone E in modern science cannot be retrospectively assigned to these historical preparations.
The main phytochemicals present in Garcinia mangostana are isoprenylated xanthones, a class of secondary metabolites with multiple reports of biological effects, including antioxidant, pro-apoptotic, anti-proliferative, antinociceptive, anti-inflammatory, neuroprotective, hypoglycemic, and anti-obesity activity. Garcinone E is one constituent within this chemically diverse family. The diversity of actions displayed by mangosteen xanthones shows that these compounds target multiple signaling pathways involved in different pathologies, placing them as valuable sources for developing new drugs to treat chronic and degenerative diseases.
The pericarp of G. mangostana is a source of xanthones and other bioactive substances. Prenylated xanthones isolated from G. mangostana have been extensively studied; some members of these compounds possess antioxidant, antitumoral, antiallergic, anti-inflammatory, antibacterial, antifungal, and antiviral properties.
Garcinone E has shown significant DPPH (2,2-diphenyl-1-picrylhydrazyl) scavenging capacity in comparative studies, when assessed alongside other xanthone derivatives from G. mangostana pericarps. This free-radical scavenging activity is consistent with the phenolic hydroxyl groups present in the garcinone E structure, which can donate hydrogen atoms to neutralize radical species.
One of the most thoroughly characterized biochemical actions of garcinone E is the inhibition of fatty acid synthase (FAS), an enzyme highly relevant to both cancer biology and metabolic disease. FAS is highly expressed in human adipocytes and cancer cells and is considered a dual therapeutic target for obesity and cancer treatment.
Garcinone E inhibited the activity of FAS in a concentration-dependent manner, with a half-inhibitory concentration (IC50) value of 3.3 μM. The inhibition kinetics showed that the inhibition of FAS by garcinone E was competitive with respect to acetyl-CoA, mixed competitive and noncompetitive with respect to malonyl-CoA, and noncompetitive to NADPH. In addition, garcinone E showed irreversible inhibition on FAS, which was different from all other xanthones studied.
Since FAS is believed to be a therapeutic target for obesity and cancer treatment, these findings suggest the clinical potential of garcinone E in the prevention and treatment of both obesity and cancer. These data, however, derive from biochemical assays conducted in vitro; no in vivo or human clinical studies of garcinone E's FAS inhibition have been published.
Garcinone E triggers programmed cell death (apoptosis) through several converging intracellular pathways. Key mechanistic observations from cell-culture studies include:
Little was known about garcinone E's effects on epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 2 (VEGFR2) activity until structure-activity relationship analyses were undertaken. Studies aimed to identify potent dual EGFR and VEGFR2 inhibitors from mangosteen-derived xanthones by analyzing the interaction of xanthones with these receptors via molecular docking experiments, with kinase activities of EGFR and VEGFR2 determined using bioluminescence assays.
In the context of breast cancer, expression of cluster of differentiation 31 (CD31), VEGF, and VEGFR2, as well as the phosphorylation of VEGFR2, were examined in tumor tissues by immunohistochemistry; garcinone E strongly reduced the expression of CD31, VEGF, and VEGFR2, as well as the phosphorylation of VEGFR2 in tumor tissues.
In vitro studies showed that garcinone E dose-dependently suppressed IL-4 + IL-13-induced expression of CD206 (a marker of M2 macrophage polarization) in both RAW 264.7 cells and differentiated THP-1 macrophages, while it did not affect LPS + IFN-γ-induced polarization to the M1-like macrophage phenotype. This selective interference with M2 polarization is relevant because tumor-associated macrophages (TAMs) polarized toward an M2 phenotype are known to promote tumor growth and metastasis.
The potent anti-inflammatory, antioxidant, and anti-apoptotic activities of garcinone E in experimental autoimmune hepatitis were correlated with its ability to enhance HO-1/Nrf2/antioxidant signaling and to inhibit the TNF-α/NF-κB/JNK axes.
In more detail:
Garcinone E has been documented to possess aromatase-inhibitory and advanced glycation end-product (AGE) inhibitory activities. Aromatase (CYP19A1) catalyzes the conversion of androgens to estrogens; its inhibition is of clinical relevance in hormone-receptor-positive cancers and in metabolic conditions associated with estrogen excess. The anti-AGE activity is potentially relevant to diabetic complications, where accumulation of protein glycation products drives tissue damage.
Research has provided insights into the mechanisms of action of structurally similar prenylated xanthones — α-mangostin, γ-mangostin, 9-hydroxycalabaxanthone, and garcinone E — derived from mangosteen pericarps, specifically in the induction of cancer cell death using triple-negative breast cancer (TNBC) cells. The presence of an isoprenyl group at position 5 in the structure of garcinone E, compared to γ-mangostin, increases its ability to increase oxidative stress and to induce a mitochondrial proton leak.
Important overarching caveat: All human-relevant data for garcinone E as a specific isolated compound derive from in vitro (cell culture) and in vivo (animal model) research. No published clinical trials in human subjects have evaluated garcinone E as an isolated compound as of the date of this article. The evidence base is therefore preliminary and pre-clinical throughout.
Study type: In vitro cytotoxicity panel study. Researchers extracted and purified six xanthone compounds from the rinds of G. mangostana L. using partitioned chromatography and tested their cytotoxic effects on a panel of 14 different human cancer cell lines, including 6 hepatoma cell lines, using the MTT method. Garcinone E was found to have a potent cytotoxic effect on all HCC cell lines as well as on the other gastric and lung cancer cell lines included in the screen. The authors suggested that garcinone E may be potentially useful for the treatment of certain types of cancer.
Evidence strength: Preliminary; in vitro only. No clinical data available.
Study type: In vitro mechanistic study in human ovarian cancer cell lines (HEY, A2780, A2780/Taxol). Twenty-four xanthones were isolated and identified from the pericarps of mangosteen, and their anti-proliferative activities were tested in ovarian cancer cells. Garcinone E was found to exhibit excellent anti-proliferative effects among the tested xanthones. Garcinone E strongly inhibited cell viability in HEY cells, with an IC50 of 7.79 ± 1.12 μM at 24 hours.
Further mechanistic studies using garcinone E in HEY, A2780, and A2780/Taxol (a paclitaxel-resistant line) cells revealed that garcinone E was able to induce apoptosis in all three cell lines, demonstrating that garcinone E may be able to overcome multidrug-resistant cells.
Evidence strength: Preliminary; in vitro only. The demonstration of activity against a paclitaxel-resistant line is a notable finding warranting further investigation.
Study type: In vitro study in HT-29 and Caco-2 colorectal cancer cell lines. The present study investigated the anticancer effects of garcinone E in mangosteen and explored its underlying mechanism of action. Garcinone E inhibited colony formation and wound healing, triggered the production of ROS, which induced mitochondrial dysfunction and apoptosis, causing cell cycle arrest at the Sub-G1 phase.
Evidence strength: Preliminary; in vitro only.
Study type: In vitro study in HeLa human cervical carcinoma cells. Results indicated that garcinone E remarkably decreased cell viability in HeLa cells in both a dose- and time-dependent manner, and efficiently reduced the clonogenic capacity of HeLa cells. Cell cycle checkpoint studies indicated arrest at G2/M-phase, and HeLa cell migration and invasion were reduced efficiently after garcinone E treatment in a dose-dependent fashion.
The authors concluded that garcinone E has a remarkable potential to act as an anti-cervical cancer chemopreventive, provided further in vivo studies are undertaken.
Evidence strength: Preliminary; in vitro only.
Study type: Combined in vitro and in vivo (murine model) study. Despite the documented anti-cancer activity of garcinone E, no reports on its therapeutic effects on breast cancer metastasis existed prior to one study; the objective was to examine the anti-cancer effects of garcinone E on metastatic breast cancer. RAW 264.7 and THP-1 cells were polarized to M2 macrophages by IL-4/IL-13 in vitro. A 4T1 mouse breast cancer model and the tail vein breast cancer metastasis model were used to explore the effect of garcinone E on breast cancer growth and metastasis in vivo.
Separate research provided mechanistic insight into how garcinone E, alongside α-mangostin, γ-mangostin, and 9-hydroxycalabaxanthone, targets oxidative mitochondrial respiration to induce cancer cell death in triple-negative breast cancer (TNBC) cells.
Evidence strength: Preliminary; primarily in vitro with some mouse-model data. No human clinical data.
Study type: In vitro and in vivo (xenograft) mechanistic study. Garcinone E inhibited the proliferation and metastasis of NPC, demonstrating promising anticancer activity. NPC cells were treated with 2.5–20 μmol/L garcinone E for 24, 48, and 72 hours. Colony formation capacity, cell cycle distribution, and in vivo xenograft experiments were assessed. MDC staining, StubRFP-sensGFP-LC3 observation, LysoBrite Blue staining, and immunofluorescence examined autophagy; Western blotting, RNA-sequencing, and RT-qPCR measured protein and mRNA levels.
The research showed that garcinone E significantly blocked autophagic flux by partially inhibiting autophagosome-lysosome fusion in the late stage of autophagy in NPC cells.
Evidence strength: Preliminary; in vitro and xenograft model. No clinical data.
Study type: Animal study using concanavalin A (Con-A)-induced autoimmune hepatitis model in mice. This study was the first to investigate the hepatoprotective capacity of garcinone E on Con-A-induced autoimmune hepatitis. Results showed that garcinone E pretreatment noticeably diminished both serum indices (transaminases, ALP, LDH, and γ-GT) and histopathological lesions of the liver. It counteracted neutrophil and CD4+ infiltration into the liver.
The results suggest the potential use of garcinone E as a novel hepatoprotective agent against autoimmune hepatitis.
Evidence strength: Preliminary; murine model only. No human clinical data.
Study type: Biochemical enzyme inhibition assay. Garcinone E inhibited the activity of FAS in a concentration-dependent manner with a half-inhibitory concentration value of 3.3 μM. Garcinone E showed irreversible inhibition on FAS, which was different from all other xanthones tested.
Evidence strength: Preliminary; biochemical assay and in vitro evidence only. Relevance to human metabolism not established.
Garcinone E has been cited as possessing advanced glycation end-product inhibitory activity. Documented activities attributed to garcinone E include cytotoxic, advanced glycation end-product inhibitory, and aromatase-inhibitory activities. AGEs are implicated in the pathogenesis of diabetic complications, neurological disorders, and atherosclerosis. The AGE-inhibitory activity of garcinone E was identified through in vitro screening but has not been developed into a clinical application in humans.
Evidence strength: Preliminary; in vitro only.
No human clinical trials have established therapeutic dosages for garcinone E. The following concentrations and doses are drawn exclusively from published in vitro and animal research:
These concentrations reflect in vitro experimental conditions and cannot be directly translated into human dosing without pharmacokinetic and pharmacodynamic data in intact biological systems.
Dedicated human safety, toxicology, or pharmacokinetic studies for garcinone E as an isolated compound are absent from the published peer-reviewed literature available at the time of this article. The following observations are drawn from the available research context:
Health conditions that Garcinone E may help support.
Body systems that Garcinone E may help support.
Go back